Prestige Consumer Healthcare (PBH) Net Income (2010 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Net Income of $46.7 million for Q4 2025, down 23.49% year-over-year from $61.0 million in Q4 2024, and up 10.63% quarter-over-quarter from $42.2 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Net Income (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Net Income history runs 16 years deep, the most recent figure standing at $46.7 million for Q4 2025.
- In Q4 2025, Net Income fell 23.49% year-over-year to $46.7 million; the TTM figure through Dec 2025 stood at $186.5 million (down 12.82% YoY), while the FY2025 annual figure was $214.6 million, up 2.52% from the prior year.
- Net Income for Q4 2025 stood at $46.7 million, up from $42.2 million in the prior quarter.
- The five-year high for Net Income was $61.0 million in Q4 2024, with the low at -$240.6 million in Q1 2023.
- The 5-year median for Net Income is $50.6 million (2021), against an average of $35.9 million.
- The sharpest annual moves came in 2023 and 2024: Net Income tumbled 561.84% in 2023, then surged 120.56% in 2024.
- Prestige Consumer Healthcare's Net Income stood at $50.2 million in 2021, then grew by 3.46% to $52.0 million in 2022, then climbed by 2.11% to $53.0 million in 2023, then climbed by 15.05% to $61.0 million in 2024, then slipped by 23.49% to $46.7 million in 2025.
- Business Quant data shows PBH's Net Income at $46.7 million in Q4 2025, $42.2 million in Q3 2025, and $47.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -69.36 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.46 Bn | 2.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |